Search
for
Sort by
Research 30 of 334
- The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome
- PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
- A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
- Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations
- PA11 A rare case of a severe papulopustular dermatosis secondary to a germline <i>EGFR</i> mutation
- Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients
- Demodicosis and rosacea: Epidemiology and significance in daily dermatologic practice
- Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Dermatologic Reactions to Targeted Therapy
- “PRIDE” Complex
- Distinctive Acne Entities
- Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer
- Acne Necrotica (Varioliformis) – Case Report
- Acne Necrotica in Its Entirety: When It Starts, and After It Evolves
- Rosacea: I. Etiology, pathogenesis, and subtype classification
- Isotretinoin treatment of acne and related disorders: An update
- Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara<sup>®</sup>) and EE/LNG (Microgynon<sup>®</sup>)
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Azelaic Acid: Mechanisms of Action and Clinical Applications
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- The management of EGFR inhibitor adverse events: a case series and treatment paradigm
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
- Dermoscopic spectrum of rosacea
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital